Th17-Dependent Nasal Hyperresponsiveness Is Mitigated by Steroid Treatment

Shusaku Ueda; Kento Miura; Hideki Kawasaki; Sawako Ogata; Norimasa Yamasaki; Shuka Miura; Akio Mori; Osamu Kaminuma

doi:10.3390/biom12050674

Th17-Dependent Nasal Hyperresponsiveness Is Mitigated by Steroid Treatment

Biomolecules. 2022 May 6;12(5):674. doi: 10.3390/biom12050674.

Authors

Shusaku Ueda¹, Kento Miura¹, Hideki Kawasaki¹, Sawako Ogata¹, Norimasa Yamasaki¹, Shuka Miura¹, Akio Mori², Osamu Kaminuma^{1

2}

Affiliations

¹ Department of Disease Model, Research Institute of Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan.
² Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Kanagawa 252-0392, Japan.

Abstract

Th17 cells are implicated in allergic inflammatory diseases, including allergic rhinitis (AR), though the effect of steroids on Th17 cell-dependent nasal responses is unclear. Herein, we investigated a nasal inflammation model elicited by allergen provocation in mice infused with Th17 cells and its responsiveness against steroid treatment. We transferred BALB/c mice with Th17 cells, which were differentiated in vitro and showed a specific reaction to ovalbumin (OVA). We challenged the transferred mice by intranasal injection of OVA and to some of them, administered dexamethasone (Dex) subcutaneously in advance. Then, we assessed immediate nasal response (INR), nasal hyperresponsiveness (NHR), and inflammatory cell infiltration into the nasal mucosa. The significant nasal inflammatory responses with massive neutrophil accumulation, INR, and NHR were induced upon allergen challenge. Allergen-induced INR and NHR were significantly suppressed by Dex treatment. This study suggested the effectiveness of steroids on Th17 cell-mediated nasal responses in AR.

Keywords: Th17 cell; dexamethasone; inflammation; mouse; nasal hyperresponsiveness.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Allergens
Animals
Mice
Nasal Mucosa
Ovalbumin
Rhinitis, Allergic* / drug therapy
Th17 Cells*

Substances

Allergens
Ovalbumin

Grants and funding

This work was supported by a Grant-in-Aid for JSPS KAKENHI to Osamu Kaminuma (No. 15K07787, 18K19561, 18K19561) and to Akio Mori (No. 18K08422, 21K08486) and funding from the OTC Self-Medication Promotion Foundation, Smoking Research Foundation, and Tanuma Green House Foundation to Osamu Kaminuma.